GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                                                                Synonyms: ATA-101 | ATA101 | compound 7a [PMID 23126648] [4] | TC-5619 | TC5619
                                 Compound class: 
                                                            Synthetic organic
                                 
                                    
                                        Comment: Bradanicline is an investigational agonist of neuronal α7 subunit-containing nicotinic acetylcholine receptors [4].
                                    
                                 | 
 | |||||||||||||||||||||||||||||||||||
| No information available. | 
| Summary of Clinical Use  | 
| Bradanicline has completed Phase 2 clinical trials as a potential treatment for the cognitive impairment associated with schizophrenia [3] and attention deficit/hyperactivity disorder (ADHD). Attenua are repurposing bradanicline as a novel intervention for refractory chronic cough [1]. | 
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References | 
| NCT03622216 | A Dose Escalation Study of Bradanicline in Refractory Chronic Cough | Phase 2 Interventional | Attenua, Inc. | ||